"We're not a one-size-fits-all CDMO," said Min Park, CCO of Matica Bio. "Our team works closely with each partner to deliver ...

Long-term follow-up shows 95% success rate, no serious complications in largest ADA-SCID gene therapy study to date ...

Bayer said it was setting up an organisation within its healthcare division to speed up and support cell and gene therapy development, following recent takeovers.

Researchers in the lab of Hans-Peter Kiem, MD, PhD, at Fred Hutch Cancer Center have devised a method that could one day treat genetic hematologic disorders by correcting how the body makes blood ...

Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic immune cell therapy products for hematology/oncology ...

Over the last 15 years, I have witnessed how cell and gene therapy (CGT) has evolved in many ways, spanning from research and development to manufacturing. Breakthroughs such as CAR-T and gene therapy ...

The rapid advancement of biomedical technologies has opened the door to curing previously untreatable diseases, offering hope for longer, healthier, and more productive lives. Innovations such as ...

Cell and gene therapies account for 20% of pipeline Parkinson's therapy bemdaneprocel in Phase 3 trial Pharma success urgently needed, says fund manager FRANKFURT, Sept 25 (Reuters) - Bayer's ...

First investigational allogeneic pluripotent stem cell derived therapy pivotal Phase III clinical trial exPDite-2 with bemdaneprocel started Phase II gene therapy trial REGENERATE-PD with AB-1005 ...

Caribou Biosciences is winnowing down for the second time in the last year, dropping a leukemia CAR-T asset and laying off 32% of staff to home in on two lead allogeneic cell therapy candidates. The ...

Patients with the most severe form of a certain inherited disease have skin that is susceptible to wounds, some that never fully heal. For years, the only treatment was supportive care, including ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...